Bachurski, Patryk, et al. “Optimal First-Line Use of Pembrolizumab in Metastatic Driver-Negative NSCLC: Monotherapy Versus Chemo-Immunotherapy (Evidence 2022–2025)”. Quality in Sport, vol. 51, Jan. 2026, p. 68252, doi:10.12775/QS.2026.51.68252.